activity
20172021
most citedCancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents

22 citations · 27 across the 4 of their papers we have counts for

collaborators
Showing stat.MEShow all

4 papers · 1 filter